Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-15 |
2024-03 |
0 |
-0.11 |
N/A |
N/A |
2024-04-02 |
2023-12 |
-0.6 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.45 |
-0.6 |
-0.15 |
-33.33% |
2023-08-14 |
2023-06 |
-0.6 |
-0.6 |
N/A |
N/A |
2023-05-10 |
2023-03 |
-0.6 |
-0.6 |
N/A |
N/A |
2023-03-07 |
2022-12 |
-1.35 |
-0.6 |
0.75 |
55.56% |
Date |
Firm |
Action |
From |
To |
2023-08-15 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2023-08-14 |
Laidlaw & Co. |
Downgrade |
Buy |
Hold |
2023-05-14 |
HC Wainwright & Co. |
Upgrade |
Neutral |
Buy |
2022-05-03 |
Wells Fargo |
Upgrade |
Equal-Weight |
Overweight |
2021-11-08 |
Raymond James |
Upgrade |
|
Market Perform |
2021-08-09 |
Raymond James |
Downgrade |
Outperform |
Market Perform |
Date |
Name |
Relation |
Quantity |
Description |
2021-05-16 |
BAFFA RAFFAELE |
Officer |
280.65K |
Stock Award(Grant) |
2022-06-21 |
BOWDEN CHRISTOPHER J |
Director |
44.17K |
Stock Award(Grant) |
2023-08-31 |
BOYLE KEVIN S. SR |
Chief Executive Officer |
798.24K |
Sale |
2021-12-21 |
DE GROOT ELEANOR M |
Officer |
237.11K |
Sale |
2021-09-01 |
HAGEN HEIDI |
Director |
145.89K |
Purchase |
2022-06-21 |
HUANG JAMES Z |
Director |
188.33K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Discovery Capital Management, LLC |
15.64M |
7.98M |
6.50% |
2023-06-29 |
Msd Partners, L.p. |
15.15M |
7.73M |
6.30% |
2023-06-29 |
Vanguard Group Inc |
9.11M |
4.65M |
3.79% |
2023-06-29 |
Laurion Capital Management, LP |
5.72M |
2.92M |
2.38% |
2023-06-29 |
Blackrock Inc. |
5.07M |
2.59M |
2.11% |
2023-06-29 |
JP Morgan Chase & Company |
2.46M |
1.26M |
1.02% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
5.82M |
2.97M |
2.42% |
2023-06-29 |
Vanguard Extended Market Index Fund |
2.99M |
1.52M |
1.24% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
1.58M |
222.13K |
0.65% |
2023-05-30 |
Fidelity Extended Market Index Fund |
1.04M |
519.38K |
0.43% |
2023-05-30 |
Fidelity Total Market Index Fund |
356.46K |
177.84K |
0.15% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
312.35K |
155.83K |
0.13% |
Split |
Date |
1 : 14 |
2024-02-01 |